Immunocompromised Therapies
retiredURL
http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2348Copied!
Version20160331Copied!
PublisherLantana EH StewardDate2022-03-03T18:46:01-05:00Purpose(Clinical Focus: This set of values contains procedures for patients who have had immunocompromising therapies.),(Data Element Scope: The intent of this data element is to identify patients who have had immunocompromising therapies. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Include codes representing immunocompromised therapies including systemic chemotherapy, radiation, corticosteroid and other immunosuppressive therapies using the ICD 9 CM, ICD 10 PCS, and SNOMED CT code systems.),(Exclusion Criteria: None.)
Expansion
Expansion error
Can't resolve code system: http://www.cms.gov/Medicare/Coding/ICD10
valueSethttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2351
valueSethttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350
valueSethttp://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2349
{
"compose" : {
"exclude" : [ ],
"include" : [ {
"valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2351" ]
}, {
"valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2350" ]
}, {
"valueSet" : [ "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2349" ]
} ]
},
"date" : "2022-03-03T18:46:01-05:00",
"meta" : {
"versionId" : "13",
"lastUpdated" : "2023-12-21T17:43:03.000-05:00",
"profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
},
"publisher" : "Lantana EH Steward",
"jurisdiction" : [ {
"coding" : [ {
"system" : "urn:iso:std:iso:3166",
"code" : "US"
} ]
} ],
"purpose" : "(Clinical Focus: This set of values contains procedures for patients who have had immunocompromising therapies.),(Data Element Scope: The intent of this data element is to identify patients who have had immunocompromising therapies. Using the Quality Data Model, this particular element will map to the Procedure category.),(Inclusion Criteria: Include codes representing immunocompromised therapies including systemic chemotherapy, radiation, corticosteroid and other immunosuppressive therapies using the ICD 9 CM, ICD 10 PCS, and SNOMED CT code systems.),(Exclusion Criteria: None.)",
"name" : "ImmunocompromisedTherapies",
"experimental" : false,
"resourceType" : "ValueSet",
"expansion" : {
"contains" : [ {
"system" : "http://hl7.org/fhir/sid/icd-9-cm",
"code" : "00.10",
"display" : "Implantation of chemotherapeutic agent",
"version" : "2013"
}, {
"system" : "http://hl7.org/fhir/sid/icd-9-cm",
"code" : "00.15",
"display" : "High-dose infusion interleukin-2 [IL-2]",
"version" : "2013"
}, {
"system" : "http://hl7.org/fhir/sid/icd-9-cm",
"code" : "17.70",
"display" : "Intravenous infusion of clofarabine",
"version" : "2013"
}, {
"system" : "http://snomed.info/sct",
"code" : "367336001",
"display" : "Chemotherapy (procedure)",
"version" : "http://snomed.info/sct/731000124108/version/20240301"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E00X05",
"display" : "Introduction of Other Antineoplastic into Skin and Mucous Membranes, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E00X0M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Skin and Mucous Membranes, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E01305",
"display" : "Introduction of Other Antineoplastic into Subcutaneous Tissue, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0130M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Subcutaneous Tissue, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E02305",
"display" : "Introduction of Other Antineoplastic into Muscle, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0230M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Muscle, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03002",
"display" : "Introduction of High-dose Interleukin-2 into Peripheral Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03003",
"display" : "Introduction of Low-dose Interleukin-2 into Peripheral Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03005",
"display" : "Introduction of Other Antineoplastic into Peripheral Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0300M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0300P",
"display" : "Introduction of Clofarabine into Peripheral Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03302",
"display" : "Introduction of High-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03303",
"display" : "Introduction of Low-dose Interleukin-2 into Peripheral Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E03305",
"display" : "Introduction of Other Antineoplastic into Peripheral Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0330M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0330P",
"display" : "Introduction of Clofarabine into Peripheral Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04002",
"display" : "Introduction of High-dose Interleukin-2 into Central Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04003",
"display" : "Introduction of Low-dose Interleukin-2 into Central Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04005",
"display" : "Introduction of Other Antineoplastic into Central Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0400M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0400P",
"display" : "Introduction of Clofarabine into Central Vein, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04302",
"display" : "Introduction of High-dose Interleukin-2 into Central Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04303",
"display" : "Introduction of Low-dose Interleukin-2 into Central Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E04305",
"display" : "Introduction of Other Antineoplastic into Central Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0430M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0430P",
"display" : "Introduction of Clofarabine into Central Vein, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05002",
"display" : "Introduction of High-dose Interleukin-2 into Peripheral Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05003",
"display" : "Introduction of Low-dose Interleukin-2 into Peripheral Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05005",
"display" : "Introduction of Other Antineoplastic into Peripheral Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0500M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0500P",
"display" : "Introduction of Clofarabine into Peripheral Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05302",
"display" : "Introduction of High-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05303",
"display" : "Introduction of Low-dose Interleukin-2 into Peripheral Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E05305",
"display" : "Introduction of Other Antineoplastic into Peripheral Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0530M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peripheral Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0530P",
"display" : "Introduction of Clofarabine into Peripheral Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06002",
"display" : "Introduction of High-dose Interleukin-2 into Central Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06003",
"display" : "Introduction of Low-dose Interleukin-2 into Central Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06005",
"display" : "Introduction of Other Antineoplastic into Central Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0600M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0600P",
"display" : "Introduction of Clofarabine into Central Artery, Open Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06302",
"display" : "Introduction of High-dose Interleukin-2 into Central Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06303",
"display" : "Introduction of Low-dose Interleukin-2 into Central Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E06305",
"display" : "Introduction of Other Antineoplastic into Central Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0630M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Central Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0630P",
"display" : "Introduction of Clofarabine into Central Artery, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E09305",
"display" : "Introduction of Other Antineoplastic into Nose, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0930M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E09705",
"display" : "Introduction of Other Antineoplastic into Nose, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0970M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E09X05",
"display" : "Introduction of Other Antineoplastic into Nose, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E09X0M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Nose, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0A305",
"display" : "Introduction of Other Antineoplastic into Bone Marrow, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0A30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Bone Marrow, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0B305",
"display" : "Introduction of Other Antineoplastic into Ear, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0B30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0B705",
"display" : "Introduction of Other Antineoplastic into Ear, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0B70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0BX05",
"display" : "Introduction of Other Antineoplastic into Ear, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0BX0M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Ear, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0C305",
"display" : "Introduction of Other Antineoplastic into Eye, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0C30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0C705",
"display" : "Introduction of Other Antineoplastic into Eye, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0C70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0CX05",
"display" : "Introduction of Other Antineoplastic into Eye, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0CX0M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Eye, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0D305",
"display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0D30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0D705",
"display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0D70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0DX05",
"display" : "Introduction of Other Antineoplastic into Mouth and Pharynx, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0DX0M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Mouth and Pharynx, External Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E305",
"display" : "Introduction of Other Antineoplastic into Products of Conception, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E705",
"display" : "Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E805",
"display" : "Introduction of Other Antineoplastic into Products of Conception, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0E80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Products of Conception, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F305",
"display" : "Introduction of Other Antineoplastic into Respiratory Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F705",
"display" : "Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F805",
"display" : "Introduction of Other Antineoplastic into Respiratory Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0F80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Respiratory Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G305",
"display" : "Introduction of Other Antineoplastic into Upper GI, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G705",
"display" : "Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G805",
"display" : "Introduction of Other Antineoplastic into Upper GI, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0G80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Upper GI, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H305",
"display" : "Introduction of Other Antineoplastic into Lower GI, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H705",
"display" : "Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H805",
"display" : "Introduction of Other Antineoplastic into Lower GI, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0H80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lower GI, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J305",
"display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J705",
"display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J805",
"display" : "Introduction of Other Antineoplastic into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0J80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Biliary and Pancreatic Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K305",
"display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K705",
"display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K805",
"display" : "Introduction of Other Antineoplastic into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0K80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Genitourinary Tract, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0L305",
"display" : "Introduction of Other Antineoplastic into Pleural Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0L30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0L705",
"display" : "Introduction of Other Antineoplastic into Pleural Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0L70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pleural Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0M305",
"display" : "Introduction of Other Antineoplastic into Peritoneal Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0M30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0M705",
"display" : "Introduction of Other Antineoplastic into Peritoneal Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0M70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Peritoneal Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N305",
"display" : "Introduction of Other Antineoplastic into Male Reproductive, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N705",
"display" : "Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N805",
"display" : "Introduction of Other Antineoplastic into Male Reproductive, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0N80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Male Reproductive, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P305",
"display" : "Introduction of Other Antineoplastic into Female Reproductive, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P705",
"display" : "Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P805",
"display" : "Introduction of Other Antineoplastic into Female Reproductive, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0P80M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Female Reproductive, Via Natural or Artificial Opening Endoscopic",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Q305",
"display" : "Introduction of Other Antineoplastic into Cranial Cavity and Brain, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Q30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Q705",
"display" : "Introduction of Other Antineoplastic into Cranial Cavity and Brain, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Q70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Cranial Cavity and Brain, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0R302",
"display" : "Introduction of High-dose Interleukin-2 into Spinal Canal, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0R303",
"display" : "Introduction of Low-dose Interleukin-2 into Spinal Canal, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0R305",
"display" : "Introduction of Other Antineoplastic into Spinal Canal, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0R30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Spinal Canal, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0S302",
"display" : "Introduction of High-dose Interleukin-2 into Epidural Space, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0S303",
"display" : "Introduction of Low-dose Interleukin-2 into Epidural Space, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0S305",
"display" : "Introduction of Other Antineoplastic into Epidural Space, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0S30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Epidural Space, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0U305",
"display" : "Introduction of Other Antineoplastic into Joints, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0U30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Joints, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0V305",
"display" : "Introduction of Other Antineoplastic into Bones, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0V30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Bones, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0W305",
"display" : "Introduction of Other Antineoplastic into Lymphatics, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0W30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Lymphatics, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Y305",
"display" : "Introduction of Other Antineoplastic into Pericardial Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Y30M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Percutaneous Approach",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Y705",
"display" : "Introduction of Other Antineoplastic into Pericardial Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://www.cms.gov/Medicare/Coding/ICD10",
"code" : "3E0Y70M",
"display" : "Introduction of Antineoplastic, Monoclonal Antibody, into Pericardial Cavity, Via Natural or Artificial Opening",
"version" : "2024"
}, {
"system" : "http://hl7.org/fhir/sid/icd-9-cm",
"code" : "99.25",
"display" : "Injection or infusion of cancer chemotherapeutic substance",
"version" : "2013"
}, {
"system" : "http://hl7.org/fhir/sid/icd-9-cm",
"code" : "99.28",
"display" : "Injection or infusion of biological response modifier [BRM] as an antineoplastic agent",
"version" : "2013"
} ],
"total" : 156,
"identifier" : "urn:uuid:c8d3dab1-68af-4307-8cef-02e469d771a9",
"timestamp" : "2024-06-14T17:59:10-04:00"
},
"title" : "Immunocompromised Therapies",
"extension" : [ {
"valueString" : "Lantana EH Author",
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
}, {
"valueDate" : "2024-06-03",
"url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
}, {
"valueDate" : "2016-03-31",
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
}, {
"url" : "http://health-samurai.io/extensions/source",
"valueCode" : "db"
} ],
"status" : "retired",
"id" : "2.16.840.1.113883.3.666.5.2348",
"url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.666.5.2348",
"identifier" : [ {
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113883.3.666.5.2348"
} ],
"version" : "20160331"
}| Title | Version | Status | Publisher | Date |
|---|---|---|---|---|
| Immunocompromised Therapies | 20160331 | active | Lantana EH Steward | - |
| Immunocompromised Therapies | 20160331 | active | Lantana EH Steward | - |